AUTOIMMUNE HAEMOLYTIC ANAEMIA IN A PATIENT TREATED WITH CAPECITABINE

• DOI: 10.2143/acb.3149
• Publication Date: 2014-07-16T16:17:05Z
• Authors: S Sideris; A Loizidou; A Georgala; F Lebrun; T Gil; Pr Awada; Pr Piccart; F Cardoso
• Keywords: Haemolysis; Lapatinib

A 61-year-old female, followed-up for a metastatic breast cancer, was admitted in our institution with conjunctival icterus, asthenia and abdominal crampoid pain. The patient included clinical trial comparing the efficiency of capecitabine monotherapy versus conjugated new biological agent randomised double blind trial. alone arm. Biological tests performed upon admission suggested diagnosis haemolytic anaemia. Moreover, direct Coombs test result twice positive indicating autoimmune Capecitabine has been reported to cause haemolysis either or combined lapatinib, each time mechanism other than immunological. In this case, is most likely factor causing an